FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2301543238> ?p ?o ?g. }

• W2301543238 endingPage "13" @default.
• W2301543238 startingPage "1" @default.
• W2301543238 abstract "The RAS and mTOR inhibitor S-trans-trans-farnesylthiosalicylic acid (FTS) is a promising anticancer agent with moderate potency, currently undergoing clinical trials as a chemotherapeutic agent. FTS has displayed its potential against a variety of cancers including endocrine resistant breast cancer. However, the poor pharmacokinetics profile attributed to its high hydrophobicity is a major hindrance for its continued advancement in clinic. One of the ways to improve its therapeutic potential would be to enhance its bioavailability to cancer tissue by developing a method for targeted delivery. In the current study, FTS was conjugated with the cancer-targeting heptamethine cyanine dye 5 to form the FTS–dye conjugate 11. The efficiency of tumor targeting properties of conjugate 11 against cancer cell growth and mTOR inhibition was evaluated in vitro in comparison with parent FTS. Cancer targeting of 11 in a live mouse model of MCF7 xenografts was demonstrated with noninvasive, near-infrared fluorescence (NIRF) imaging. The results from our studies clearly suggest that the bioavailability of FTS is indeed improved as indicated by log P values and cancer cell uptake. The FTS–dye conjugate 11 displayed higher potency (IC50 = 16.8 ± 0.5 μM) than parent FTS (IC50 = ∼51.3 ± 1.8 μM) and inhibited mTOR activity in the cancer cells at a lower concentration (12.5 μM). The conjugate 11 was shown to be specifically accumulated in tumors as observed by in vivo NIRF imaging, organ distribution, and ex vivo tumor histology along with cellular level confocal microscopy. In conclusion, the conjugation of FTS with cancer-targeting heptamethine cyanine dye improved its pharmacological profile." @default.
• W2301543238 created "2016-06-24" @default.
• W2301543238 creator A5003856071 @default.
• W2301543238 creator A5020214618 @default.
• W2301543238 creator A5024202469 @default.
• W2301543238 creator A5039136616 @default.
• W2301543238 creator A5044544424 @default.
• W2301543238 creator A5060384421 @default.
• W2301543238 creator A5063343992 @default.
• W2301543238 creator A5068275315 @default.
• W2301543238 creator A5085491808 @default.
• W2301543238 creator A5090415469 @default.
• W2301543238 date "2016-12-16" @default.
• W2301543238 modified "2023-10-17" @default.
• W2301543238 title "Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye" @default.
• W2301543238 cites W1675910794 @default.
• W2301543238 cites W1836179493 @default.
• W2301543238 cites W1911110831 @default.
• W2301543238 cites W1972417377 @default.
• W2301543238 cites W1988193392 @default.
• W2301543238 cites W1988313934 @default.
• W2301543238 cites W1989917629 @default.
• W2301543238 cites W1992000766 @default.
• W2301543238 cites W1994088225 @default.
• W2301543238 cites W1994892692 @default.
• W2301543238 cites W1997233622 @default.
• W2301543238 cites W1998327957 @default.
• W2301543238 cites W1999135455 @default.
• W2301543238 cites W2006091725 @default.
• W2301543238 cites W2009911191 @default.
• W2301543238 cites W2013765163 @default.
• W2301543238 cites W2013956549 @default.
• W2301543238 cites W2014136875 @default.
• W2301543238 cites W2024237542 @default.
• W2301543238 cites W2026976628 @default.
• W2301543238 cites W2031705055 @default.
• W2301543238 cites W2031922993 @default.
• W2301543238 cites W2036456322 @default.
• W2301543238 cites W2039825885 @default.
• W2301543238 cites W2040173160 @default.
• W2301543238 cites W2058767217 @default.
• W2301543238 cites W2059244758 @default.
• W2301543238 cites W2065917789 @default.
• W2301543238 cites W2066765132 @default.
• W2301543238 cites W2067796149 @default.
• W2301543238 cites W2076226743 @default.
• W2301543238 cites W2088209210 @default.
• W2301543238 cites W2089959908 @default.
• W2301543238 cites W2090576400 @default.
• W2301543238 cites W2104978230 @default.
• W2301543238 cites W2108326951 @default.
• W2301543238 cites W2111337537 @default.
• W2301543238 cites W2116269880 @default.
• W2301543238 cites W2123251409 @default.
• W2301543238 cites W2130996329 @default.
• W2301543238 cites W2132446533 @default.
• W2301543238 cites W2136596688 @default.
• W2301543238 cites W2139660349 @default.
• W2301543238 cites W2148060280 @default.
• W2301543238 cites W2148570339 @default.
• W2301543238 cites W2150375936 @default.
• W2301543238 doi "https://doi.org/10.1021/acs.molpharmaceut.5b00906" @default.
• W2301543238 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5815365" @default.
• W2301543238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26992462" @default.
• W2301543238 hasPublicationYear "2016" @default.
• W2301543238 type Work @default.
• W2301543238 sameAs 2301543238 @default.
• W2301543238 citedByCount "24" @default.
• W2301543238 countsByYear W23015432382017 @default.
• W2301543238 countsByYear W23015432382018 @default.
• W2301543238 countsByYear W23015432382019 @default.
• W2301543238 countsByYear W23015432382020 @default.
• W2301543238 countsByYear W23015432382021 @default.
• W2301543238 countsByYear W23015432382022 @default.
• W2301543238 countsByYear W23015432382023 @default.
• W2301543238 crossrefType "journal-article" @default.
• W2301543238 hasAuthorship W2301543238A5003856071 @default.
• W2301543238 hasAuthorship W2301543238A5020214618 @default.
• W2301543238 hasAuthorship W2301543238A5024202469 @default.
• W2301543238 hasAuthorship W2301543238A5039136616 @default.
• W2301543238 hasAuthorship W2301543238A5044544424 @default.
• W2301543238 hasAuthorship W2301543238A5060384421 @default.
• W2301543238 hasAuthorship W2301543238A5063343992 @default.
• W2301543238 hasAuthorship W2301543238A5068275315 @default.
• W2301543238 hasAuthorship W2301543238A5085491808 @default.
• W2301543238 hasAuthorship W2301543238A5090415469 @default.
• W2301543238 hasBestOaLocation W23015432382 @default.
• W2301543238 hasConcept C121332964 @default.
• W2301543238 hasConcept C121608353 @default.
• W2301543238 hasConcept C126322002 @default.
• W2301543238 hasConcept C134306372 @default.
• W2301543238 hasConcept C150903083 @default.
• W2301543238 hasConcept C181389837 @default.
• W2301543238 hasConcept C185592680 @default.
• W2301543238 hasConcept C197336794 @default.
• W2301543238 hasConcept C202751555 @default.
• W2301543238 hasConcept C207001950 @default.
• W2301543238 hasConcept C26291073 @default.

• next